
1. antimicrob agents chemother. 1997 jul;41(7):1571-4.

pharmacokinetics hyperimmune anti-human immunodeficiency virus immunoglobulin 
in persons aids.

fletcher cv(1), goodroad bk, cummins lm, henry k, balfour hh jr, rhame fs.

author information: 
(1)college pharmacy, university minnesota academic health center,
minneapolis 55455, usa.

hyperimmune anti-human immunodeficiency virus immunoglobulin (hivig) an
intravenous immunoglobulin prepared hiv-infected asymptomatic donors 
cd4 cell count greater 400 cells/microl high titer antibody to
hiv-1 p24 protein. twelve persons aids received four doses hmg (two 50
mg/kg body weight two 200 mg/kg) every 28 days. pharmacokinetics
were evaluated measurement anti-p24 antibody. hivig well tolerated, and
all participants completed study. three subjects receiving
pneumocystis carinii pneumonia (pcp) prophylaxis developed pcp. mean value
for hivig clearance 3.02 ml/kg/day 50 mg/kg 3.65 ml/kg/day 200
mg/kg (p = 0.027); mean trough antibody titers (reciprocal units) 1,442 
and 4,428, respectively. study indicates high titers anti-p24
antibody maintained monthly administration schedule hivig and
that short-term safety acceptable. comparisons evaluate therapeutic
potential hivig justified.

doi: 10.1128/aac.41.7.1571 
pmcid: pmc163961
pmid: 9210687  [indexed medline]

